Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 May;157(2):153-65.
doi: 10.1038/bjp.2008.349.

Viral vectors: from virology to transgene expression

D Bouard  1 , D Alazard-Dany, F-L Cosset
Affiliations
Review

Viral vectors: from virology to transgene expression

D Bouard et al. Br J Pharmacol. 2009 May.

Abstract

In the late 1970s, it was predicted that gene therapy would be applied to humans within a decade. However, despite some success, gene therapy has still not become a routine practise in medicine. In this review, we will examine the problems, both experimental and clinical, associated with the use of viral material for transgenic insertion. We shall also discuss the development of viral vectors involving the most important vector types derived from retroviruses, adenoviruses, herpes simplex viruses and adeno-associated viruses.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The four main viral vectors: plasmids and viral particles. (a) Recombinant AAV vector. (b) Retroviral vector. (c) Gutless adenoviral vector. (d) Amplicon vector derived from HSV-1. ITR, inverted terminal repeat; L, left; R, right; ψ, a, encapsidation signal; oriS, replication origin.
Figure 2
Figure 2
Overview of gene therapy clinical trials worldwide. (a) Number of trials initiated per year, (b) vectors used and (c) indications addressed. Updated information available from the Journal of Gene Medicine: http://www.wiley.co.uk/genmed/clinical. Reproduced with the permission from Wiley and Son Ltd.
Figure 3
Figure 3
From wild-type virus to replication-defective viral vectors. Outline of the possible modifications of viral properties required to transform a virus into a gene transfer vector.
Figure 4
Figure 4
A few targeting and re-targeting options for viral vectors. Retargeting is necessary to alter the tropism of the viral vectors to reach more efficiently the desired target cells and/or prevent transduction of non-target cells.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Aiuti A, Slavin S, Aker M, Ficara F, Deola S, Mortellaro A, et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science. 2002;296:2410–2413. - PubMed
    1. Andreadis S, Roth C, Doux JL, Morgan J, Yarmush M. Large-scale processing of recombinant retroviruses for gene therapy. Biotechnol Prog. 1999;15:1–11. - PubMed
    1. Ashworth J, Havranek JJ, Duarte CM, Sussman D, Monnat RJ, Jr, Stoddard BL, et al. Computational redesign of endonuclease DNA binding and cleavage specificity. Nature. 2006;441:656–659. - PMC - PubMed
    1. Baum C, Kustikova O, Modlich U, Li Z, Fehse B. Mutagenesis and oncogenesis by chromosomal insertion of gene transfer vectors. Hum Gene Ther. 2006;17:253–263. - PubMed
    1. Beck C, Uramoto H, Boren J, Akyurek LM. Tissue-specific targeting for cardiovascular gene transfer. Potential vectors and future challenges. Curr Gene Ther. 2004;4:457–467. - PubMed

Publication types